Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Amberg-Johnson

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Antimicrobial Agents and Chemotherapy|November 21, 2018
Host Cell Metabolism Contributes to Delayed-Death Kinetics of Apicoplast Inhibitors in Toxoplasma gondiiKatherine Amberg-Johnson, Ellen Yeh
Msphere|July 23, 2019
Erratum for Foe et al., "The Toxoplasma gondii Active Serine Hydrolase 4 Regulates Parasite Division and Intravacuolar Parasite Architecture"Ian T Foe, Ouma Onguka, Katherine Amberg-Johnson, et al.
Msphere|September 21, 2018
The <i>Toxoplasma gondii</i> Active Serine Hydrolase 4 Regulates Parasite Division and Intravacuolar Parasite ArchitectureIan T Foe, Ouma Onguka, Katherine Amberg-Johnson, et al.
Elife|August 23, 2017
Small molecule inhibition of apicomplexan FtsH1 disrupts plastid biogenesis in human pathogensKatherine Amberg-Johnson, Sanjay B Hari, Suresh M Ganesan, et al.
Plos Biology|February 7, 2019
A mutagenesis screen for essential plastid biogenesis genes in human malaria parasitesYong Tang, Thomas R Meister, Marta Walczak, et al.
Journal of Chemical Information and Modeling|February 20, 2025
Predicting Resistance to Small Molecule Kinase InhibitorsAnu Nagarajan, Katherine Amberg-Johnson, Evan Paull, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Discovery of 2H-Pyrrolo[3,4‑<i>c</i>]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation CalculationsEric Therrien, Shulu Feng, Katherine Amberg-Johnson, et al.
Iscience|May 1, 2024
Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activityAlan S Futran, Tao Lu, Katherine Amberg-Johnson, et al.
Journal of Medicinal Chemistry|December 12, 2024
Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an <i>In Silico</i> Enabled Drug Discovery PlatformHideyuki Igawa, Zef A Konst, Eric Therrien, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Antimicrobial Agents and Chemotherapy|November 21, 2018
Host Cell Metabolism Contributes to Delayed-Death Kinetics of Apicoplast Inhibitors in Toxoplasma gondiiKatherine Amberg-Johnson, Ellen Yeh
Msphere|July 23, 2019
Erratum for Foe et al., "The Toxoplasma gondii Active Serine Hydrolase 4 Regulates Parasite Division and Intravacuolar Parasite Architecture"Ian T Foe, Ouma Onguka, Katherine Amberg-Johnson, et al.
Msphere|September 21, 2018
The <i>Toxoplasma gondii</i> Active Serine Hydrolase 4 Regulates Parasite Division and Intravacuolar Parasite ArchitectureIan T Foe, Ouma Onguka, Katherine Amberg-Johnson, et al.
Elife|August 23, 2017
Small molecule inhibition of apicomplexan FtsH1 disrupts plastid biogenesis in human pathogensKatherine Amberg-Johnson, Sanjay B Hari, Suresh M Ganesan, et al.
Plos Biology|February 7, 2019
A mutagenesis screen for essential plastid biogenesis genes in human malaria parasitesYong Tang, Thomas R Meister, Marta Walczak, et al.
Journal of Chemical Information and Modeling|February 20, 2025
Predicting Resistance to Small Molecule Kinase InhibitorsAnu Nagarajan, Katherine Amberg-Johnson, Evan Paull, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Discovery of 2H-Pyrrolo[3,4‑<i>c</i>]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation CalculationsEric Therrien, Shulu Feng, Katherine Amberg-Johnson, et al.
Iscience|May 1, 2024
Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activityAlan S Futran, Tao Lu, Katherine Amberg-Johnson, et al.
Journal of Medicinal Chemistry|December 12, 2024
Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an <i>In Silico</i> Enabled Drug Discovery PlatformHideyuki Igawa, Zef A Konst, Eric Therrien, et al.
Pageof 1